Compare Enveric Biosciences Inc (ENVB) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kraft Heinz Co — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Kraft Heinz Co trades at $22.48 (market cap $26.06B). The key difference: Kraft Heinz Co is far larger — about 3895.4× Enveric Biosciences Inc's market cap, and Kraft Heinz Co pays a 7.28% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Kraft Heinz Co for 129 Days on average.
| ENVB | KHC | |
|---|---|---|
Market Cap | $6.69M | $26.06B |
Volume | 41,141 | 15,326,651 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $27.62 |
52-Week Low | $1.27 | $21.21 |
Typical Hold Time | 14 Days | 129 Days |
Enterprise Value | -$1.60M | $42.38B |
Dividend Yield | — | 7.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Kraft Heinz (KHC) trades at $22.48, up 2.04% today, with a bearish technical signal but recent earnings beats. The stock shows a low P/E of 13.04 and P/B of 0.72, yet profitability is weak with a -13.64% net margin. Cash flow improved to $1.46B in 2025, but a $5.85B net loss and high debt of $19.22B pose challenges. News highlights dividend stability and brand revitalization efforts, such as new Philadelphia cream cheese flavors.
Outlook remains cautious; the stock offers value with a dividend yield near 6%, but turnaround success is critical. Risks include sustained volume declines and debt servicing. Analysts are mixed with a $23.78 consensus target, suggesting limited upside. Institutional interest exists, but weak fundamentals warrant careful monitoring for recovery signs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
